Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRAF | P15056 | 4/20 | 0.42 |
| ▸ | KDR | P35968 | 4/20 | 0.42 |
| ▸ | PIK3CA | P42336 | 3/20 | 0.37 |
| ▸ | AKT1 | P31749 | 2/20 | 0.37 |
| ▸ | DYRK1A | Q13627 | 9/20 | 0.36 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.36 |
| ▸ | PIK3CG | P48736 | 3/20 | 0.35 |
| ▸ | FSCN1 | Q16658 | 1/20 | 0.34 |
| ▸ | MTOR | P42345 | 1/20 | 0.33 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2858244 | 0.83 | BRAF (0.48) | BRAFKDRPIK3CAAKT1DYRK1A | |
| SCHEMBL2851100 | 0.82 | BRAF (0.42) | BRAFKDRPIK3CAAKT1DYRK1A | |
| SCHEMBL3512826 | 0.75 | BRAF (0.53) | BRAFKDRPIK3CADYRK1APDPK1 | |
| SCHEMBL3511827 | 0.75 | BRAF (0.44) | BRAFKDRPIK3CAAKT1DYRK1A | |
| SCHEMBL3512003 | 0.74 | BRAF (0.54) | BRAFKDRPIK3CADYRK1APIK3CG | |
| SCHEMBL3512360 | 0.74 | BRAF (0.36) | BRAFKDRPIK3CAAKT1DYRK1A | |
| SCHEMBL2861355 | 0.73 | BRAF (0.57) | BRAFKDRPIK3CA | |
| SCHEMBL2853575 | 0.73 | BRAF (0.62) | BRAFKDR | |
| SCHEMBL13185059 | 0.72 | BRAF (0.56) | BRAFKDRPIK3CAAKT1MTOR | |
| SCHEMBL3512217 | 0.72 | BRAF (0.46) | BRAFKDRPIK3CADYRK1APDPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8344135-B2 | Heterocyclic compound and use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2013-01-01 | — | — | US | disclosed |
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2010-09-30 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100249119-A1 | HETEROCYCLIC COMPOUND AND USE THEREOF | BRAF, NRAS, RAF1 | BRAF 1/4885KDR 983/4885PIK3CA 198/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.